Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:MRNA News 15 January 2026 - 26 January 2026

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna stock pulls back after a sharp rally as investors weigh U.S. vaccine backlash risk

Moderna shares fell 6.09% to $48.71 Friday after CEO Stéphane Bancel said the company will scale back new late-stage vaccine trials, citing U.S. resistance and policy delays. The drop followed a midweek rally on positive cancer vaccine data with Merck. Investors await Moderna’s Feb. 13 results for further updates. U.S. markets are closed until Monday.
24 January 2026
····
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings

Pfizer shares fell 1.9% to $25.62 Friday as the stock went ex-dividend, nearly matching the $0.43 payout. The drop outpaced the health-care sector, with Moderna tumbling over 7% and Merck down 1%. Policy changes under Health Secretary Robert F. Kennedy Jr. have unsettled vaccine makers. Pfizer reports quarterly results and hosts a webcast on Feb. 3.
23 January 2026
·······
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials

Moderna shares jumped 4.2% to $51.87 in after-hours trading Thursday after CEO Stephane Bancel said the company will halt new late-stage vaccine trials, citing resistance from U.S. officials and an unreliable U.S. market. The move follows weak COVID vaccine demand and comes as Moderna and Merck reported their experimental cancer vaccine cut melanoma recurrence or death by 49% over five years in a mid-stage study.
23 January 2026
····
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running

Moderna shares rose 7.7% to $53.65 Thursday after five-year data showed its personalized cancer vaccine with Merck’s Keytruda cut melanoma recurrence or death risk by 49%. The phase 2b trial enrolled 157 patients and met its primary endpoint. Investors await phase 3 trial updates and Moderna’s Feb. 13 results call. The stock had jumped 15.8% Wednesday on the initial data release.
22 January 2026
····
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data

Moderna shares held steady at $49.81 premarket Thursday after surging 15.8% on five-year melanoma data for its cancer vaccine with Merck. The vaccine-Keytruda combo cut recurrence or death risk by 49% versus Keytruda alone. U.S. vaccine-policy uncertainty is adding risk for the sector. Investors await Moderna’s Feb. 13 earnings call for updates on oncology data and 2026 sales.
22 January 2026
······
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda, its best-selling cancer drug, ahead of competition and cheaper alternatives hitting the market later this decade. The company recently told investors it expects new growth drivers to generate up to $70 billion in revenue by the mid-2030s. (Reuters) Merck managed
21 January 2026
·······
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play

New York, January 20, 2026, 14:02 EST — Regular session Merck & Co (MRK.N) shares held steady on Tuesday following news that the company’s personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda (pembrolizumab). By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11. (Reuters) Why it matters now: Keytruda stands as Merck’s top-selling drug, with crucial patents set to expire in 2028, tightening the timeline on what comes next for the company. Back in 2022, Merck told Reuters that
20 January 2026
·····
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA

New York, Jan 17, 2026, 06:02 EST — The market has closed. Moderna’s stock climbed 6.3% Friday, closing at $41.83 as the rally that’s been choppy all week gained traction. Since January 12, shares have surged roughly 24%, boosted by a 17% jump on January 13, followed by a short pullback on January 15. (Investing.com) Investors aren’t focused just on Friday’s headline. They’re sizing up Moderna’s broader challenge: overcoming the post-pandemic drop in COVID vaccine sales and proving it can balance cash flow while advancing new products in late-stage trials. Wall Street will be closed Monday in observance of Martin
17 January 2026
·····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
1 2 3 4

Stock Market Today

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

7 February 2026
Northern Star Resources fell 1.7% to A$26.77 Friday, extending losses as gold miners and the broader market declined. MGX Resources completed its A$50 million purchase of a 50% stake in the Central Tanami Gold Project from Northern Star. The All Ordinaries Gold index dropped 3.24%. CME Group raised COMEX gold futures margin requirements to 9% amid volatility.
PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop